Charles Schwab
APLT

Charles Schwab’s Applied Therapeutics APLT Stock Holding History

Charles Schwab’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-403,514
Closed -$126K – 3464
2025
Q2 		$126K Sell
403,514
-229,015
-36% -$88.6K ﹤0.01% 3404
2025
Q1 		$309K Sell
632,529
-68,307
-10% -$40.2K ﹤0.01% 3200
2024
Q4 		$600K Sell
700,836
-34,381
-5% -$216K ﹤0.01% 3084
2024
Q3 		$6.25M Buy
735,217
+457,940
+165% +$2.7M ﹤0.01% 2257
2024
Q2 		$1.29M Buy
277,277
+252,773
+1,032% +$1.2M ﹤0.01% 2838
2024
Q1 		$167K Hold
24,504
– – ﹤0.01% 3260
2023
Q4 		$82.1K Hold
24,504
– – ﹤0.01% 3363
2023
Q3 		$61K Hold
24,504
– – ﹤0.01% 3390
2023
Q2 		$31.4K Buy
+24,504
New +$32.5K ﹤0.01% 3500
2022
Q2 		– Sell
-38,968
Closed -$83K – 3545
2022
Q1 		$83K Sell
38,968
-6,111
-14% -$16.4K ﹤0.01% 3447
2021
Q4 		$404K Buy
45,079
+1,743
+4% +$22.9K ﹤0.01% 3217
2021
Q3 		$720K Sell
43,336
-317
-0.7% -$5.47K ﹤0.01% 3006
2021
Q2 		$908K Buy
43,653
+4,507
+12% +$85.3K ﹤0.01% 2969
2021
Q1 		$735K Buy
39,146
+5,042
+15% +$109K ﹤0.01% 2948
2020
Q4 		$751K Sell
34,104
-91
-0.3% -$1.9K ﹤0.01% 2862
2020
Q3 		$710K Buy
34,195
+2,180
+7% +$56.7K ﹤0.01% 2773
2020
Q2 		$1.16M Buy
32,015
+11,529
+56% +$482K ﹤0.01% 2582
2020
Q1 		$670K Buy
20,486
+6,845
+50% +$277K ﹤0.01% 2607
2019
Q4 		$373K Buy
+13,641
New +$234K ﹤0.01% 2927

Other funds holding APLT

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Charles Schwab's APLT Position: Q3 2025 in Review

Charles Schwab sold out of Applied Therapeutics (APLT) in Q3 2025, closing a stake of 403,514 shares — an estimated $126K sold.

Charles Schwab first reported a position in APLT in Q4 2019 and held it in 19 quarters. The position peaked at $6.25M in Q3 2024. 70 funds tracked by Wall St. Rank hold APLT as of Q3 2025.

  • Charles Schwab reported no remaining Applied Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Charles Schwab sold 403,514 Applied Therapeutics shares in Q3 2025, an estimated $126K.
  • Charles Schwab first reported a position in Applied Therapeutics in Q4 2019 and held it in 19 quarters.
  • Charles Schwab's Applied Therapeutics position peaked at $6.25M in Q3 2024.
  • 70 funds tracked by Wall St. Rank held Applied Therapeutics as of Q3 2025.

Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.